Systemic inflammation and mortality in chronic obstructive pulmonary disease
- PMID: 17487253
- DOI: 10.1139/y06-093
Systemic inflammation and mortality in chronic obstructive pulmonary disease
Abstract
Cardiovascular diseases and cancer (especially lung cancer) are leading causes of morbidity and mortality in patients with chronic obstructive pulmonary disease (COPD). Some have implicated systemic inflammation, which is commonly observed in COPD, as the potential mechanistic bridge between COPD and these disorders. This concept has been supported by animal studies especially in rabbits, which have clearly demonstrated the effect of local lung inflammation on systemic inflammation and on the progression of atherosclerosis and by cross-sectional population-based studies, which have shown a significant relationship between systemic inflammation, as measured by circulating C-reactive protein (CRP) and the risk of cardiovascular diseases in COPD patients. These data have been further extended by a recent study that has elucidated the temporal nature of the relationship between systemic inflammation and the risk of cardiovascular events and cancer in COPD patients. This study showed that baseline CRP levels predicted the incidence of cardiovascular events and cancer-specific mortality over 7 to 8 years of follow-up. CRP levels also predicted all-cause mortality. Collectively, these data indicate that systemic inflammation may play an important role in mediating the extra-pulmonary complications of COPD. Systemic inflammation may contribute substantially to the overall morbidity and mortality of COPD patients.
Similar articles
-
[Chronic obstructive pulmonary disease and cardiovascular system].Tuberk Toraks. 2008;56(4):464-71. Tuberk Toraks. 2008. PMID: 19123087 Review. Turkish.
-
Dynamic pulmonary hyperinflation and low grade systemic inflammation in stable COPD patients.Eur Rev Med Pharmacol Sci. 2011 Sep;15(9):1068-73. Eur Rev Med Pharmacol Sci. 2011. PMID: 22013730
-
The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease.Eur J Intern Med. 2008 Mar;19(2):104-8. doi: 10.1016/j.ejim.2007.04.026. Eur J Intern Med. 2008. PMID: 18249305
-
Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease.Clin Sci (Lond). 2008 Oct;115(7):225-32. doi: 10.1042/CS20070382. Clin Sci (Lond). 2008. PMID: 18307413
-
Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease.Can J Physiol Pharmacol. 2005 Jan;83(1):8-13. doi: 10.1139/y04-116. Can J Physiol Pharmacol. 2005. PMID: 15759045 Review.
Cited by
-
Blood Levels of Indicators of Lower Respiratory Tract Damage in Chronic Bronchitis in Patients with Abdominal Obesity.Diagnostics (Basel). 2022 Jan 25;12(2):299. doi: 10.3390/diagnostics12020299. Diagnostics (Basel). 2022. PMID: 35204398 Free PMC article.
-
Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future.Eur J Clin Pharmacol. 2009 Sep;65(9):853-71. doi: 10.1007/s00228-009-0682-z. Epub 2009 Jun 26. Eur J Clin Pharmacol. 2009. PMID: 19557399 Review.
-
Inhalation of environmental stressors & chronic inflammation: autoimmunity and neurodegeneration.Mutat Res. 2009 Mar 31;674(1-2):62-72. doi: 10.1016/j.mrgentox.2008.09.016. Epub 2008 Oct 11. Mutat Res. 2009. PMID: 18977456 Free PMC article. Review.
-
Associations of pulmonary function with serum biomarkers and dialysis adequacy in patients undergoing peritoneal dialysis.Clin Exp Nephrol. 2016 Dec;20(6):951-959. doi: 10.1007/s10157-016-1244-1. Epub 2016 Feb 11. Clin Exp Nephrol. 2016. PMID: 26868146
-
Lower extremity and carotid artery disease in COPD.ERJ Open Res. 2016 Oct 26;2(4):00037-2016. doi: 10.1183/23120541.00037-2016. eCollection 2016 Oct. ERJ Open Res. 2016. PMID: 28053972 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous